HK Stock Market Move | IMMUNEONCO-B(01541) is now up nearly 6% IMM2510 combination chemotherapy clinical trial completes dosing for the first patient.

IMMUNEONCO-B (01541) is up nearly 6%, rising 4.09% to HK$4.83 as of the time of writing, with a trading volume of HK$13.7229 million. In terms of news, ImmunoGen announced that the Ib/II phase clinical trial of IMM2510 in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has successfully dosed its first patient. After the safety lead-in period, the company plans to enroll first-line patients in the aforementioned clinical trial, with preliminary clinical data expected to be released as early as the second half of 2025, including data from first-line NSCLC patients. In addition, ImmunoGen recently announced the sale of industrial land located in Kangqiao Industrial Park in Pudong New Area, Shanghai, with a land area of approximately 28,763 square meters, to Zhangjiang Group for a cash consideration of up to RMB 98.19 million. Furthermore, ImmunoGen recently completed a private placement of approximately HK$230 million, with 70% of the proceeds intended to provide funding for pivotal clinical research in China, including combination therapy with Tepotinib and Tislelizumab, and the remaining 30% for general corporate purposes.